Published in Curr Opin Immunol on April 01, 2005
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev (2006) 3.30
NK cells promote transplant tolerance by killing donor antigen-presenting cells. J Exp Med (2006) 2.45
Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci U S A (2006) 1.77
Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res (2011) 1.62
MicroRNA function in NK-cell biology. Immunol Rev (2013) 0.96
The Notch ligands Jagged2, Delta1, and Delta4 induce differentiation and expansion of functional human NK cells from CD34+ cord blood hematopoietic progenitor cells. Biol Blood Marrow Transplant (2009) 0.93
Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. J Transl Med (2015) 0.89
Present and Future of Allogeneic Natural Killer Cell Therapy. Front Immunol (2015) 0.86
Selection and expansion of natural killer cells for NK cell-based immunotherapy. Cancer Immunol Immunother (2016) 0.84
PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells. Oncotarget (2016) 0.84
Rapid generation of a functional NK-cell compartment. Blood (2007) 0.83
In vivo monitoring of natural killer cell trafficking during tumor immunotherapy. Magn Reson Insights (2014) 0.83
Activation of hepatic natural killer cells and control of liver-adapted lymphoma in the murine model of cytomegalovirus infection. Med Microbiol Immunol (2008) 0.82
Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress. Front Immunol (2015) 0.82
The significance of non-T-cell pathways in graft rejection: implications for transplant tolerance. Transplantation (2010) 0.82
Natural Killer Cell Immunotherapy: From Bench to Bedside. Front Immunol (2015) 0.81
Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy. Front Immunol (2014) 0.81
Low Dose Focused Ultrasound Induces Enhanced Tumor Accumulation of Natural Killer Cells. PLoS One (2015) 0.80
Adoptive immunotherapy against ovarian cancer. J Ovarian Res (2016) 0.79
An overview on non-T cell pathways in transplant rejection and tolerance. Curr Opin Organ Transplant (2010) 0.78
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 12.75
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med (2005) 12.18
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood (2011) 4.57
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A (2008) 4.26
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood (2005) 3.90
Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood (2003) 3.88
Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol (2005) 3.81
Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med (2014) 3.08
The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant (2006) 2.93
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood (2009) 2.75
Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol (2012) 2.68
Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood (2006) 2.68
Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood (2008) 2.34
Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood (2002) 2.20
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest (2009) 2.08
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood (2006) 2.06
Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood (2002) 2.03
NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. Br J Haematol (2010) 1.80
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood (2011) 1.74
NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). Blood (2002) 1.63
Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood (2005) 1.56
Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood (2005) 1.54
A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood (2003) 1.45
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood (2006) 1.41
Haploidentical hematopoietic transplantation: current status and future perspectives. Blood (2011) 1.40
Increased ratio of CD31+/CD42- microparticles to endothelial progenitors as a novel marker of atherosclerosis in hypercholesterolemia. Arterioscler Thromb Vasc Biol (2006) 1.36
Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunol Rev (2006) 1.34
Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. Curr Opin Oncol (2007) 1.27
A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation. Br J Haematol (2009) 1.26
Mutational landscape of AML with normal cytogenetics: biological and clinical implications. Blood Rev (2012) 1.24
CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood (2010) 1.21
Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1. Blood (2008) 1.20
Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood (2006) 1.18
Killer-cell immunoglobulin-like receptors reactivity and outcome of stem cell transplant. Curr Opin Hematol (2012) 1.15
Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood (2005) 1.14
Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. Curr Opin Immunol (2009) 1.13
NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis (2007) 1.11
TLR3 essentially promotes protective class I-restricted memory CD8⁺ T-cell responses to Aspergillus fumigatus in hematopoietic transplanted patients. Blood (2011) 1.09
Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice. Haematologica (2008) 1.07
Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation. Blood Cells Mol Dis (2007) 1.06
Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood (2004) 1.06
"Designed" grafts for HLA-haploidentical stem cell transplantation. Blood (2013) 1.03
Homozygosity for human leucocyte antigen-C ligands of KIR2DL1 is associated with increased risk of relapse after human leucocyte antigen-C-matched unrelated donor haematopoietic stem cell transplantation. Br J Haematol (2005) 1.01
Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2013) 1.00
Microparticles derived from endothelial progenitor cells in patients at different cardiovascular risk. Atherosclerosis (2007) 0.97
The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases. Haematologica (2005) 0.97
Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation. Best Pract Res Clin Haematol (2011) 0.97
Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma. Hematol J (2004) 0.96
Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. Cancer Res (2007) 0.95
Protection of killer antiidiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation. Infect Immun (2002) 0.94
Alloreactive natural killer cells in mismatched hematopoietic stem cell transplantation. Blood Cells Mol Dis (2004) 0.94
Dendritic cells pulsed with fungal RNA induce protective immunity to Candida albicans in hematopoietic transplantation. J Immunol (2002) 0.93
Natural killer cell alloreactivity for leukemia therapy. J Immunother (2005) 0.92
Haploidentical hematopoietic stem cell transplantation with a megadose T-cell-depleted graft: harnessing natural and adaptive immunity. Semin Oncol (2012) 0.91
Genetically-determined hyperfunction of the S100B/RAGE axis is a risk factor for aspergillosis in stem cell transplant recipients. PLoS One (2011) 0.91
Natural killer cell recognition of missing self and haploidentical hematopoietic transplantation. Semin Cancer Biol (2006) 0.91
Tolerance induction by megadose hematopoietic progenitor cells: expansion of veto cells by short-term culture of purified human CD34(+) cells. Blood (2002) 0.90
The haploidentical option for high-risk haematological malignancies. Blood Cells Mol Dis (2007) 0.90
Notch1 modulates mesenchymal stem cells mediated regulatory T-cell induction. Eur J Immunol (2012) 0.90
Experts' considerations on HLA-haploidentical stem cell transplantation. Eur J Haematol (2014) 0.89
A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). Haematologica (2008) 0.89
Immune regulatory activity of CD34+ progenitor cells: evidence for a deletion-based mechanism mediated by TNF-alpha. Blood (2004) 0.87
The impact of donor natural killer cell alloreactivity on allogeneic hematopoietic transplantation. Transpl Immunol (2005) 0.87